Liver disease accounts for two million deaths annually and is responsible for 4% of all
deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related …

Autoimmune hepatitis is an inflammatory disease of the liver of unknown cause that may
progress to liver cirrhosis and end stage liver failure if diagnosis is overlooked and treatment …

Background Effective treatments for patients with primary biliary cholangitis are limited.
Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential …

Autoimmune hepatitis (AIH) is an inflammatory liver disease, affecting mainly females,
characterized by elevated transaminase and immunoglobulin G (IgG) levels, interface …

Seladelpar efficacy and safety at 3 months in patients with... : Hepatology Seladelpar
efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a …

The modern Gastroenterology have witnessed an essential stride since Helicobacter pylori
was first found in the stomach and then its pathogenic effect was discovered. According to …

Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease
characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the …

Background Autoimmune hepatitis (AIH) varies significantly in incidence and prevalence
across countries and regions. We aimed to examine global, regional, and national trends in …

Background & Aims The Primary Biliary Cholangitis (PBC) Obeticholic Acid (OCA)
International Study of Efficacy (POISE) randomized, double-blind, placebo-controlled trial …

Background & Aims The aim of this study was to quantify the global epidemiology of primary
sclerosing cholangitis (PSC), alongside the incidence of liver transplantation, cancer, and …